Ranica

• A study to assess the effects of zigakibart on IgA nephropathy. Recruiting
  2024-519699-24-00 4 2026-04-23 IgA nephropathy
• Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease Recruiting
  2025-521752-26-00 4 2026-04-22 Complement-Mediated Kidney Disease
• Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting
  2023-509331-83-00 5 2021-07-28 complement 3 glomerulopathy
• Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm … Recruiting
  2025-523306-33-00 4 2026-03-12 Idiopathic Nephrotic Syndrome
• Atacicept in Multiple Glomerular Diseases Recruiting
  2024-518465-10-00 4 2025-12-12 Multiple Autoimmune Glomerular Diseases
• Phase 2a Study of ALXN1920 in PMN Recruiting
  2025-520780-40-00 4 2025-11-26 Primary Mebranous Nephropathy (PMN)
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting
  2024-519345-30-00 5 2025-11-12 IgA nephropathy
• A multicenter, single-arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody treatment to iptacopan treatm … Recruiting
  2023-504550-35-00 5 2025-04-03 Atypical Hemolytic Uremic Syndrome (aHUS)
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 5 2023-10-02 Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
• Long-term efficacy, safety and tolerability of LNP023 in C3G or IC-MPGN Recruiting
  2023-509343-27-00 11 2019-10-28 C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
• A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended recruitment
  2024-518457-42-00 4 2025-08-28 chronic kidney disease
• A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifer … Ended recruitment
  2023-504625-39-00 5 2023-05-18 C3 glomerulopathy (C3G) or immune complex membranoproliferative glomer
• Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended recruitment
  2023-505495-30-00 5 2019-02-01 Immunoglobulin A Nephropathy (IgAN)
• A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dial … Ended
  2023-503984-41-00 5 2023-08-02 Hyyperkalemia in CKD stage IIIB to V patients
• A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patient … Ended
  2024-514130-20-00 5 2022-04-04 complement 3 glomerulopathy (C3G)/immune complex membranoproliferativ
• An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplan … Ended
  2024-511544-36-00 4 2021-12-21 complement 3 glomerulopathy (C3G)/immune complex membranoproliferative
• Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrom … Ended
  2024-515857-93-00 4 2021-12-17 Primary Membranous Nephropathy
• Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Th … Ended
  2024-513744-28-00 4 2021-10-22 Membranous nephropathy
• A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease Ended
  2023-506897-11-00 5 2021-10-18 Non-diabetic chronic kidney disease
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy

Showing 1–20 of 20 trials